EVALUATION OF SCH51048 IN AN EXPERIMENTAL-MODEL OF PULMONARY ASPERGILLOSIS

被引:17
作者
ALLENDOERFER, R
LOEBENBERG, D
RINALDI, MG
GRAYBILL, JR
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX
[2] UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX
[3] AUDIE L MURPHY VET AFFAIRS HOSP,SAN ANTONIO,TX
[4] SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ
关键词
D O I
10.1128/AAC.39.6.1345
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison with mortality in controls (P < 0.05). Both SCH51048 and SCH39304 at higher doses (30 and 50 mg/kg) reduced the number of viable Aspergillus fumigatus organisms in lung tissue (P < 0.05). In the present model, itraconazole neither delayed mortality nor significantly reduced the counts in tissue at the doses used, We conclude that SCH51048 is an effective therapy for murine pulmonary aspergillosis.
引用
收藏
页码:1345 / 1348
页数:4
相关论文
empty
未找到相关数据